Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals-Reference-Cited by-同舟云学术

Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals

Published:2024-08-28 Issue: Volume: Page:
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Perez Raul¹,Suman Julie D²,Reynolds Joe¹

Affiliation:

1. Noble International LLC, Orlando, Florida, USA

2. AptarGroup Inc, Congers, New York, USA

Funder

Boehringer Ingelheim Pharmaceuticals, Inc

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2024.2394112

Reference48 articles.

2. Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases

3. Center for Biologics Evaluation and Research. Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry. Silver Spring (MD): Food & Drug Administration (US); [updated 2020 May 6; cited 2023 Aug 31]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-demonstrating-interchangeability-reference-product-guidance-industry

4. Center for Drug Evaluation and Research. Supplement Approval: Fulfillment of Postmarketing Requirement. Silver Spring (MD): US Food and Drug Administration; [cited 2023 Sep 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761058Orig1s008ltr.pdf

5. S.1695 - 110th Congress (2007-2008): Biologics Price Competition and Innovation Act of 2007. 2008 Nov 19.) Available from: https://www.congress.gov/bill/110th-congress/senate-bill/1695